{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:33:24Z","timestamp":1784871204759,"version":"3.55.0"},"reference-count":47,"publisher":"The Endocrine Society","issue":"10","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060152"],"award-info":[{"award-number":["82060152"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"publisher","award":["22JR5RA648"],"award-info":[{"award-number":["22JR5RA648"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Innovation Platform Foundation of Gansu Provincial Hospital","award":["ZX-62000001-2021-193"],"award-info":[{"award-number":["ZX-62000001-2021-193"]}]},{"name":"Lanzhou Science and Technology Plan","award":["2020-ZD-20"],"award-info":[{"award-number":["2020-ZD-20"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Although Hashimoto's thyroiditis (HT) is one of most common autoimmune thyroid diseases, its treatment remains focused on symptom relief. The soluble epoxide hydrolase (sEH) shows potential functions as a drug target in alleviating some autoimmune diseases; however, we seldom know its role in HT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The protein expression of sEH and related downstream molecules were evaluated by immunohistochemistry, Western blotting, ELISA, or immunofluorescence staining. RNA sequencing of tissue samples was performed to analyze differential genes and dysregulated pathways in HT and controls. The thyroid follicular epithelial cells (TFECs) and rat HT model were used to verify the biological function of sEH and the inhibition role of adamantyl-ureido-dodecanoic acid (AUDA) in HT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The sEH was significantly upregulated in HT patients compared with healthy individuals. Transcriptome sequencing showed cytokine-related pathways and chemokine expression; especially chemokine CXCL10 and its receptor CXCR3 were aberrant in HT patients. In TFECs and a rat HT model, blocking sEH by AUDA inhibitor could effectively inhibit the autoantibody, proinflammatory nuclear kappa factor B (NF-\u03baB) signaling, chemokine CXCL10\/CXCR3 expression, and type-1 helper CD4+ T cells.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our findings suggest that sEH\/NF-\u03baB p65\/CXCL10-CXCR3 might be promising therapeutic targets for HT.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgae163","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T20:06:56Z","timestamp":1710360416000},"page":"2579-2588","source":"Crossref","is-referenced-by-count":7,"title":["Inhibiting Soluble Epoxide Hydrolase Suppresses NF-\u03baB p65 Signaling and Reduces CXCL10 Expression as a Potential Therapeutic Target in Hashimoto's Thyroiditis"],"prefix":"10.1210","volume":"109","author":[{"given":"Jing","family":"Feng","sequence":"first","affiliation":[{"name":"The First School of Clinical Medicine, Lanzhou University , Lanzhou, Gansu 730099 , China"},{"name":"Department of Endocrinology, Gansu Provincial Hospital , Lanzhou, Gansu 730099 , China"},{"name":"Clinical Research Center for Metabolic Disease, Gansu Provincial Hospital , Lanzhou, Gansu 730099 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Biotherapy Center, Gansu Provincial Hospital , Lanzhou, Gansu 730099 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Pathology, Gansu Provincial Hospital , Lanzhou, Gansu 730099 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingwen","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Gansu Provincial Hospital , Lanzhou, Gansu 730099 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruilan","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Gansu Provincial Hospital , Lanzhou, Gansu 730099 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Gansu Provincial Hospital , Lanzhou, Gansu 730099 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4769-4375","authenticated-orcid":false,"given":"Limin","family":"Tian","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Lanzhou University , Lanzhou, Gansu 730099 , China"},{"name":"Department of Endocrinology, Gansu Provincial Hospital , Lanzhou, Gansu 730099 , China"},{"name":"Clinical Research Center for Metabolic Disease, Gansu Provincial Hospital , Lanzhou, Gansu 730099 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,3,13]]},"reference":[{"issue":"10","key":"2024091609270307900_dgae163-B1","doi-asserted-by":"crossref","first-page":"102649","DOI":"10.1016\/j.autrev.2020.102649","article-title":"Hashimoto's thyroiditis: an update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation","volume":"19","author":"Ralli","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2024091609270307900_dgae163-B2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.semcancer.2019.05.019","article-title":"Thyroid autoimmune disorders and cancer","volume":"64","author":"Ferrari","year":"2020","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"2024091609270307900_dgae163-B3","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.autrev.2014.10.016","article-title":"Autoimmune thyroid disorders","volume":"14","author":"Antonelli","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"12","key":"2024091609270307900_dgae163-B4","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1590\/S0100-879X2012007500168","article-title":"The increased but non-predominant expression of Th17- and Th1-specific cytokines in Hashimoto's thyroiditis but not in Graves\u2019 disease","volume":"45","author":"Qin","year":"2012","journal-title":"Braz J Med Biol Res"},{"issue":"5","key":"2024091609270307900_dgae163-B5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1089\/thy.2008.0423","article-title":"Increases of the Th1\/Th2 cell ratio in severe Hashimoto's disease and in the proportion of Th17 cells in intractable Graves\u2019 disease","volume":"19","author":"Nanba","year":"2009","journal-title":"Thyroid"},{"issue":"7684","key":"2024091609270307900_dgae163-B6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature25013","article-title":"Inhibition of soluble epoxide hydrolase prevents diabetic retinopathy","volume":"552","author":"Hu","year":"2017","journal-title":"Nature"},{"issue":"4","key":"2024091609270307900_dgae163-B7","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1124\/pr.113.007781","article-title":"The pharmacology of the cytochrome P450 epoxygenase\/soluble epoxide hydrolase axis in the vasculature and cardiovascular disease","volume":"66","author":"Fleming","year":"2014","journal-title":"Pharmacol Rev"},{"issue":"10","key":"2024091609270307900_dgae163-B8","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/nrd2875","article-title":"Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases","volume":"8","author":"Imig","year":"2009","journal-title":"Nat Rev Drug Discovery"},{"issue":"6","key":"2024091609270307900_dgae163-B9","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.3945\/an.116.012245","article-title":"The role of cytochrome P450 epoxygenases, soluble epoxide hydrolase, and epoxyeicosatrienoic acids in metabolic diseases","volume":"7","author":"Xu","year":"2016","journal-title":"Adv Nutr"},{"key":"2024091609270307900_dgae163-B10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pharmthera.2017.06.006","article-title":"Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases","volume":"180","author":"Wagner","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"573","key":"2024091609270307900_dgae163-B11","doi-asserted-by":"crossref","first-page":"eabb1206","DOI":"10.1126\/scitranslmed.abb1206","article-title":"An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer's disease","volume":"12","author":"Ghosh","year":"2020","journal-title":"Sci Transl Med"},{"key":"2024091609270307900_dgae163-B12","doi-asserted-by":"crossref","first-page":"107859","DOI":"10.1016\/j.pharmthera.2021.107859","article-title":"Soluble ligands as drug targets for treatment of inflammatory bowel disease","volume":"226","author":"Tong","year":"2021","journal-title":"Pharmacol Ther"},{"issue":"9","key":"2024091609270307900_dgae163-B13","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.3390\/ijms22094650","article-title":"A soluble epoxide hydrolase inhibitor, 1-TrifluoromethoxyPhenyl-3-(1-propionylpiperidin-4-yl) urea, ameliorates experimental autoimmune encephalomyelitis","volume":"22","author":"Jonnalagadda","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2024091609270307900_dgae163-B14","doi-asserted-by":"crossref","first-page":"9074","DOI":"10.1096\/fj.202000415R","article-title":"Soluble epoxide hydrolase inhibitor, TPPU, increases regulatory T cells pathway in an arthritis model","volume":"34","author":"Trindade-da-Silva","year":"2020","journal-title":"FASEB J"},{"issue":"1","key":"2024091609270307900_dgae163-B15","doi-asserted-by":"crossref","first-page":"8993","DOI":"10.1038\/s41598-019-45299-5","article-title":"Prophylactic inhibition of soluble epoxide hydrolase delays onset of nephritis and ameliorates kidney damage in NZB\/W F1 mice","volume":"9","author":"Klocke","year":"2019","journal-title":"Sci Rep"},{"key":"2024091609270307900_dgae163-B16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.bbi.2019.07.014","article-title":"Anti-inflammatory treatment with a soluble epoxide hydrolase inhibitor attenuates seizures and epilepsy-associated depression in the LiCl-pilocarpine post-status epilepticus rat model","volume":"81","author":"Shen","year":"2019","journal-title":"Brain Behav Immun"},{"issue":"9","key":"2024091609270307900_dgae163-B17","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/S0006-2952(02)00952-8","article-title":"Structural refinement of inhibitors of urea-based soluble epoxide hydrolases","volume":"63","author":"Morisseau","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"2024091609270307900_dgae163-B18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bbi.2014.07.016","article-title":"Soluble epoxide hydrolase activity regulates inflammatory responses and seizure generation in two mouse models of temporal lobe epilepsy","volume":"43","author":"Hung","year":"2015","journal-title":"Brain Behav Immun"},{"issue":"37","key":"2024091609270307900_dgae163-B19","doi-asserted-by":"crossref","first-page":"13646","DOI":"10.1073\/pnas.0605908103","article-title":"Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors","volume":"103","author":"Schmelzer","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"46","key":"2024091609270307900_dgae163-B20","doi-asserted-by":"crossref","first-page":"16747","DOI":"10.1073\/pnas.0508081102","article-title":"The nti-inflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase","volume":"102","author":"Liu","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"2024091609270307900_dgae163-B21","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1210\/clinem\/dgae163","article-title":"Inhibiting Soluble Epoxide Hydrolase suppresses NF-\u03baB p65 signaling and reduces CXCL10 expression as a potential therapeutic target in Hashimoto's thyroiditis","volume":"109","author":"Feng","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2024091609270307900_dgae163-B22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3389\/fendo.2018.00629","article-title":"IL-34 Expression is reduced in Hashimoto's thyroiditis and associated with thyrocyte apoptosis","volume":"9","author":"Wang","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2024091609270307900_dgae163-B23","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1210\/jc.2012-2555","article-title":"Interferon-gamma and tumor necrosis factor-alpha sustain secretion of specific CXC chemokines in human thyrocytes: a first step toward a differentiation between autoimmune and tumor-related inflammation?","volume":"98","author":"Rotondi","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"22","key":"2024091609270307900_dgae163-B24","doi-asserted-by":"crossref","first-page":"19649","DOI":"10.1074\/jbc.M200743200","article-title":"T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities","volume":"277","author":"Lee","year":"2002","journal-title":"J Biol Chem"},{"issue":"10","key":"2024091609270307900_dgae163-B25","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1158\/1940-6207.CAPR-19-0341","article-title":"Pioglitazone, nuclear receptors, and aerodigestive prevention","volume":"12","author":"Ondrey","year":"2019","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"2024091609270307900_dgae163-B26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/08916934.2020.1855428","article-title":"Dioscin alleviates hashimoto's thyroiditis by regulating the SUMOylation of IRF4 to promote CD4(+)CD25(+)Foxp3(+) treg cell differentiation","volume":"54","author":"Yongjun","year":"2021","journal-title":"Autoimmunity"},{"issue":"4","key":"2024091609270307900_dgae163-B27","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/01.RES.0000237390.92932.37","article-title":"Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function","volume":"99","author":"Seubert","year":"2006","journal-title":"Circ Res"},{"issue":"1","key":"2024091609270307900_dgae163-B28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1146\/annurev-pharmtox-011112-140244","article-title":"Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health","volume":"53","author":"Morisseau","year":"2013","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"2024091609270307900_dgae163-B29","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41467-022-28120-2","article-title":"Lymphocyte infiltration and thyrocyte destruction are driven by stromal and immune cell components in Hashimoto's thyroiditis","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"key":"2024091609270307900_dgae163-B30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.trsl.2021.01.004","article-title":"Efficacy of novel bispecific antibody targeting TNF-alpha\/CXCL10 in the treatment of experimental arthritis","volume":"232","author":"Kang","year":"2021","journal-title":"Transl Res"},{"issue":"4","key":"2024091609270307900_dgae163-B31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ana.24494","article-title":"A destructive feedback loop mediated by CXCL10 in central nervous system inflammatory disease","volume":"78","author":"Roberts","year":"2015","journal-title":"Ann Neurol"},{"issue":"8","key":"2024091609270307900_dgae163-B32","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/art.38676","article-title":"Correlation of CXCL10, tumor necrosis factor receptor type II, and galectin 9 with disease activity in juvenile dermatomyositis","volume":"66","author":"Bellutti Enders","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"2024091609270307900_dgae163-B33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2265.2006.02447.x","article-title":"Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves\u2019 disease, and modulation by methimazole therapy","volume":"64","author":"Antonelli","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2024091609270307900_dgae163-B34","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3109\/08916934.2011.561818","article-title":"Serum CXCL10 levels and neuromuscular manifestations in patients with autoimmune thyroid diseases","volume":"44","author":"Cakir","year":"2011","journal-title":"Autoimmunity"},{"issue":"3","key":"2024091609270307900_dgae163-B35","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1365-2249.2002.01778.x","article-title":"Graves\u2019 disease is associated with an altered CXCR3 and CCR5 expression in thyroid-derived compared to peripheral blood lymphocytes","volume":"127","author":"Aust","year":"2002","journal-title":"Clin Exp Immunol"},{"issue":"9343","key":"2024091609270307900_dgae163-B36","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/S0140-6736(02)11395-X","article-title":"Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases","volume":"360","author":"Dubuquoy","year":"2002","journal-title":"Lancet"},{"issue":"6","key":"2024091609270307900_dgae163-B37","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1183\/09031936.00023310","article-title":"Role of NF-kappaB and PPAR-gamma in lung inflammation induced by monocyte-derived microparticles","volume":"37","author":"Neri","year":"2011","journal-title":"Eur Respir J"},{"issue":"5","key":"2024091609270307900_dgae163-B38","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S0016-5085(03)00271-3","article-title":"Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis","volume":"124","author":"Dubuquoy","year":"2003","journal-title":"Gastroenterology"},{"issue":"9","key":"2024091609270307900_dgae163-B39","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/jmv.24504","article-title":"Hepatitis C virus infection induces elevation of CXCL10 in human brain microvascular endothelial cells","volume":"88","author":"Liu","year":"2016","journal-title":"J Med Virol"},{"issue":"5","key":"2024091609270307900_dgae163-B40","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.autrev.2008.12.002","article-title":"CXCL10 and autoimmune diseases","volume":"8","author":"Lee","year":"2009","journal-title":"Autoimmun Rev"},{"issue":"2","key":"2024091609270307900_dgae163-B41","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/icb.2010.158","article-title":"CXCR3 ligands: redundant, collaborative and antagonistic functions","volume":"89","author":"Groom","year":"2011","journal-title":"Immunol Cell Biol"},{"key":"2024091609270307900_dgae163-B42","doi-asserted-by":"crossref","first-page":"879824","DOI":"10.3389\/fimmu.2022.879824","article-title":"A global regulatory network for dysregulated gene expression and abnormal metabolic signaling in immune cells in the microenvironment of Graves\u2019 disease and Hashimoto's thyroiditis","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"2024091609270307900_dgae163-B43","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40618-020-01477-1","article-title":"An update on the pathogenesis of Hashimoto's thyroiditis","volume":"44","author":"Weetman","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"2024091609270307900_dgae163-B44","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1586\/17512433.2016.1157468","article-title":"Novel therapies for thyroid autoimmune diseases","volume":"9","author":"Fallahi","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"2024091609270307900_dgae163-B45","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","article-title":"Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"3","key":"2024091609270307900_dgae163-B46","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cvr\/cvv018","article-title":"Cardiomyocyte-specific expression of CYP2J2 prevents development of cardiac remodelling induced by angiotensin II","volume":"105","author":"He","year":"2015","journal-title":"Cardiovasc Res"},{"issue":"7","key":"2024091609270307900_dgae163-B47","doi-asserted-by":"crossref","first-page":"e40258","DOI":"10.1371\/journal.pone.0040258","article-title":"8,9-Epoxyeicosatrienoic acid inhibits antibody production of B lymphocytes in mice","volume":"7","author":"Gao","year":"2012","journal-title":"PloS One"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae163\/57079338\/dgae163.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/10\/2579\/59135792\/dgae163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/10\/2579\/59135792\/dgae163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T09:30:02Z","timestamp":1726479002000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/10\/2579\/7628109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,13]]},"references-count":47,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,3,13]]},"published-print":{"date-parts":[[2024,9,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae163","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,3,13]]}}}